Creative Planning Invests $249,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Creative Planning bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 6,382 shares of the company’s stock, valued at approximately $249,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Amalgamated Bank grew its position in Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after acquiring an additional 513 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Mirum Pharmaceuticals by 10.6% during the second quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock worth $315,000 after buying an additional 883 shares during the last quarter. Quest Partners LLC raised its stake in shares of Mirum Pharmaceuticals by 7,513.3% during the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after buying an additional 1,127 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Mirum Pharmaceuticals by 7.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,641 shares of the company’s stock valued at $448,000 after acquiring an additional 1,246 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in Mirum Pharmaceuticals by 11.7% during the 1st quarter. Russell Investments Group Ltd. now owns 17,481 shares of the company’s stock worth $439,000 after acquiring an additional 1,825 shares during the period.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Evercore ISI raised their price target on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Cantor Fitzgerald raised their target price on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Friday, October 11th. Leerink Partners lifted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Finally, Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $56.82.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $42.00 on Monday. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -18.34 and a beta of 1.16. The company has a debt-to-equity ratio of 1.34, a current ratio of 3.28 and a quick ratio of 3.09. The company has a 50 day simple moving average of $39.93 and a 200 day simple moving average of $35.40. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $45.23.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.